Levi & Korsinsky, LLP announces that an OCGN class action lawsuit has been filed on behalf of investors who purchased Ocugen, Inc. (OCGN) securities between February 2, 2021, and June 10, 2021, For more on the OCGN Lawsuit please contact us today.

According to the Ocugen lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration (“FDA”) was insufficient to support an Emergency Use Authorization (“EUA”), (ii) Ocugen would not file a EUA with the FDA, (iii) as a result of the foregoing, the Company’s financial statements, as well as Defendants’ statements about Ocugen’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

TO LEARN MORE ABOUT THE OCGN CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Ocugen you have until August 17, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com